Abstract
Background Cognitive impairment is a feature of Parkinson’s Disease (PD) from the early stages, but currently, no treatment for cognitive deficits in PD is available. Erythropoietin (EPO) has been studied for its potential neuroprotective properties in neurologic disorders with a beneficial action on cognition.
Objective To evaluate if NeuroEPO, a new formulation of EPO with low content of sialic acid, improves the cognitive function in PD patients.
Methods A double-blind, randomized, placebo-controlled physician lead trial was conducted. The sample was composed of 26 PD patients (HY stages I-II), where 15 received intranasal NeuroEPO for 5 weeks, and another age and gender-matched 11 patients were randomly assigned to the Placebo. All the samples received 9 months of intensive NeuroEPO treatment during a post-trial. The cognitive functions were assessed using a comprehensive neuropsychological battery before, one week, and 6 months after the first intervention and one week after a 9months post-trial. The effects of NeuroEPO were evaluated using a multivariate linear mixed-effects model using a latent variable for cognition instead of the raw neuropsychological scores.
Results A significant and direct effect of the Dose of NeuroEPO (p=0.00003) was found on cognitive performance with a strong positive influence of educational level (p=0.0032) and negative impact of age (p=0.0063).
Conclusions These preliminary results showed a positive effect of NeuroEPO on cognition in PD patients with better benefit for younger and higher educated patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04110678
Funding Statement
This study was funded by the National Natural Science Foundation of China (NSFC) project 61871105, the CNS Program of UESTC Y0301902610100201, and the Ministry of Public Health and Ministry of Science and Technology of the Republic of Cuba
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of two institutions: International Center for Neurological Restoration (CIREN) and the Center for Molecular Immunology (CIM), Cuba, following all the guidelines for clinical trials of the Ministry of Public Health of the Republic of Cuba.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* sharing the first authorship
↵** sharing the co-corresponding authorship.
Financial disclosure: The authors don’t have financial issues to declare.
Funding sources for the study: The study was funded by the Ministry of Public Health and the Ministry of Science and Technology of the Republic of Cuba and the grant 61871105 of the National Nature Science Foundation of China NSFC and the CNS Program of UESTC (No. Y0301902610100201).
Table 2 revised; Delete Table 3; Figure 2 revised
Data Availability
All data produced are available online at https://doi.org/10.17605/OSF.IO/M8SJP
